GLPwatch
The Effect of Semaglutide on Pituitary Function
NCT04865744 · Completed
Last updated 2026-05-28This clinical trial tests whether the medication semaglutide affects growth hormone levels in healthy individuals.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, double-blind diagnostic study
Participants 10 people
Who can join Ages 18–50 · all sexes Healthy volunteers accepted.
Timeline Started 2021-05 · est. completion 2021-09
Where 1 site · Estonia
What this study is testing ClinicalTrials.gov NCT04865744 ↗
Description as written by the study sponsor.
The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.
Treatments tested
- Semaglutide 7 MG Oral Tablet also known as Rybelsus 7 mg Drug
Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
- Placebo Drug
Placebo tablet is taken after an overnight fast with up to120 ml of water.
- Semaglutide 14 MG Oral Tablet also known as Rybelsus 14 mg Drug
Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.
| Main thing measured | Growth hormone peak |
|---|---|
| Sponsor | University of Tartu |
| Conditions studied | Healthy |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04865744 ↗